NCT05332756 Long-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives (LAMORA)
| NCT ID | NCT05332756 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Tiantan Hospital |
| Condition | Moyamoya Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2022-05-01 |
| Primary Completion | 2026-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2022-05-01 with a primary completion date of 2026-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to investigate the long-term outcomes of conservative management in patients with moyamoya disease and their first-degree relatives, and provide potential pathogenesis of moyamoya disease.
Eligibility Criteria
Inclusion Criteria: 1. Patients with age between 2-60 years; 2. A clinical diagnosis of moyamoya disease, including unilateral and bilateral disease. 3. Patients are medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation. 4. Capable of understanding the purpose and risk of the study and has signed the informed consent. If the participant is not capable of this at the time of enrollment, a legally authorized representative will provide written informed consent in accordance with all regulations. 5. Ability to comply with study follow-up. Exclusion Criteria: 1. Concomitant other diseases, including systemic vasculitis, neurofibroma, meningitis, sickle cell disease, down's syndrome, and previous basilar radiotherapy. 2. Patients with cardiogenic embolism, including a history of atrial fibrillation, valvular disease or cardiac valve replacement. 3. Patients are allergic to the contrast agents. 4. Patients are treated with direct, indirect, or combined revascularization depending on the presentation. 5. Physical or subjective failure to cooperate with the examination or serious comorbid diseases. 6. Patients are unable or unlikely to return for follow-up visits. 7. Any other reasons that, in the opinion of the investigators, make the participant unsuitable for enrollment.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05332756 clinical trial?
This trial is open to participants of all sexes, aged 2 Years or older, up to 60 Years, studying Moyamoya Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05332756 currently recruiting?
Yes, NCT05332756 is actively recruiting participants. Contact the research team at zhangqianchina@yahoo.com for enrollment information.
Where is the NCT05332756 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT05332756 clinical trial?
NCT05332756 is sponsored by Beijing Tiantan Hospital. The trial plans to enroll 400 participants.